Denosumab is a human monoclonal antibody that targets receptor activator of nuclear factor-κB (RANK)-ligand and is widely used as a bone-modifying agent to prevent or delay SREs associated with bone metastases from solid tumors, particularly prostate cancer [13]. This evidence concerns the gene TNFRSF11A and prostate carcinoma.